Nascent Biotech, Inc. (NBIO)
OTCMKTS
· Delayed Price · Currency is USD
0.0090
+0.0015 (20.00%)
Feb 28, 2025, 3:00 PM EST
Nascent Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.30M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| SANUWAVE Health | 29.30M |
| Silence Therapeutics | 43.26M |
Nascent Biotech News
- 7 months ago - Nascent Biotech Presents at the July Emerging Growth Conference - Accesswire
- 11 months ago - Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run - Accesswire
- 1 year ago - Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System - Accesswire
- 1 year ago - Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates - Accesswire
- 1 year ago - Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued - Accesswire
- 1 year ago - Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk - Accesswire
- 1 year ago - Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier - Accesswire
- 1 year ago - Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer - Accesswire